A detailed history of Susquehanna International Group, LLP transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 18,351 shares of ATHA stock, worth $12,295. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,351
Previous 61,821 70.32%
Holding current value
$12,295
Previous $163,000 95.09%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.42 - $3.43 $18,257 - $149,102
-43,470 Reduced 70.32%
18,351 $8,000
Q2 2024

Aug 15, 2024

SELL
$1.92 - $2.71 $60,672 - $85,636
-31,600 Reduced 33.83%
61,821 $163,000
Q1 2024

May 07, 2024

BUY
$2.24 - $4.15 $99,104 - $183,608
44,243 Added 89.97%
93,421 $255,000
Q4 2023

Feb 14, 2024

BUY
$1.39 - $2.46 $28,771 - $50,919
20,699 Added 72.68%
49,178 $119,000
Q3 2023

Nov 14, 2023

SELL
$1.9 - $3.16 $36,214 - $60,229
-19,060 Reduced 40.09%
28,479 $57,000
Q2 2023

Aug 11, 2023

SELL
$2.36 - $3.59 $7,500 - $11,409
-3,178 Reduced 6.27%
47,539 $140,000
Q1 2023

May 16, 2023

SELL
$2.26 - $4.22 $58,007 - $108,314
-25,667 Reduced 33.6%
50,717 $126,000
Q4 2022

Feb 14, 2023

BUY
$2.76 - $3.71 $37,483 - $50,385
13,581 Added 21.62%
76,384 $242,000
Q3 2022

Nov 14, 2022

SELL
$2.93 - $3.96 $513,505 - $694,021
-175,258 Reduced 73.62%
62,803 $187,000
Q2 2022

Aug 15, 2022

SELL
$2.74 - $13.43 $18,574 - $91,041
-6,779 Reduced 2.77%
238,061 $726,000
Q1 2022

May 16, 2022

SELL
$8.96 - $13.51 $2.25 Million - $3.39 Million
-251,035 Reduced 50.62%
244,840 $3.31 Million
Q4 2021

Feb 14, 2022

BUY
$9.17 - $16.39 $2.42 Million - $4.32 Million
263,666 Added 113.55%
495,875 $6.46 Million
Q3 2021

Nov 15, 2021

BUY
$9.15 - $11.09 $624,432 - $756,825
68,244 Added 41.62%
232,209 $2.18 Million
Q2 2021

Aug 11, 2021

BUY
$10.24 - $20.87 $1.68 Million - $3.42 Million
163,965 New
163,965 $1.68 Million

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $25.3M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.